HCHilla Chen

Hilla Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hilla Chen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease

    by Hilla Chen, Gilad Segev, Michal Mazaki-Tovi

    Background: Renal secondary hyperparathyroidism (RHPT) is an inevitable consequence of chronic kidney disease (CKD). Paricalcitol might safely attenuate RHPT and proteinuria. Hypothesis/Objective: Paricalcitol decreases parathyroid hormone (PTH) and proteinuria in dogs with CKD. Animals: Thirteen dogs with naturally acquired CKD. Methods: Placebo-controlled clinical trial. Dogs were randomly allocated to receive a placebo or paricalcitol (14 ng/kg/day) in a crossover design of 2, 12-week arms. Dogs were evaluated every 3 weeks. Associations between treatment, visit, and the outcome variables were assessed using generalized estimating equations. Results: PTH decreased by 22% (95% CI, 7%–35%, p = 0.006) in the paricalcitol-treated dogs and increased by 18% (95% CI, 2%–37%, p = 0.022) in the placebo-treated dogs with each visit. FGF-23 at 12 weeks increased compared with baseline in the paricalcitol-treated (mean 6941 pg/mL, 95% CI, 1781–20 057 vs. 489 pg/mL, 95% CI, 188–1272, p < 0.001, respectively), but not in the placebo-treated dogs (696 pg/mL, 95% CI, 316–1531 vs. 955 pg/mL, 95% CI, 308–2963, p = 0.529). Urine protein-to-creatinine ratio at 12 weeks increased compared with baseline in the placebo-treated (0.8, 95% CI, 0.3–1.3 vs. 0.5, 95% CI, 0.2–0.9, p = 0.04, respectively), but not in the paricalcitol-treated dogs (0.6, 95% CI, 0.3–0.9 vs. 1.0, 95% CI, 0.1–1.8, p = 0.35). Ionized calcium was unchanged between baseline and 12 weeks in the paricalcitol- and placebo-treated groups (1.3 mmol/L, 95% CI, 1.29–1.35 and 1.34, 95% CI, 1.27–1.40 vs. 1.30, 95% CI, 1.25–1.35, p = 0.12 and 1.28, 95% CI, 1.24–1.32, p = 0.034, respectively). However, 7/13 dogs developed mild hypercalcemia. Adverse effects were not reported by the owners. Conclusion and Clinical Importance: Paricalcitol attenuated RHPT and stabilized renal proteinuria in dogs with CKD.


  • Open Access

    Clinical findings, prognostic factors, and outcome of protein-losing nephropathy in cats: A retrospective study

    by Noam Sugar, Hilla Chen, Gilad Segev

    Background: Primary glomerular disease resulting in protein-losing nephropathy (PLN) is an uncommon cause of chronic kidney disease in cats, yet is important to recognize because it warrants specific treatment that impacts outcome. Hypothesis/Objective: Characterize clinicopathologic findings, prognostic indicators, and short- (≤30 days) and long-term survival of cats with PLN. Animals: Thirty-seven cats with naturally occurring PLN. Methods: Medical records of cats with PLN admitted to a veterinary teaching hospital were retrospectively reviewed. Results: Median age was 3 years (range, 1.5-11.5 years) and 17/37 (46%) were males. Short-term survival was 57%. The estimated median survival time of all cats was 424 days (95% confidence interval [CI], 0-1098 days). Common clinical signs included lethargy (57%), edema (46%) and weight loss (35%). Edema was more common in short-term survivors compared with nonsurvivors (odds ratio [OR], 0.21; 95% CI, 0.05-0.86-20.4; P = .04). Serum creatinine concentration at presentation was negatively associated with long-term survival (OR, 1.3; 95% CI, 1.03-1.52; P = .01). Administration of immunosuppressive and antiproteinuric medications was more common among short-term survivors compared with nonsurvivors (18/20 [90%] vs 9/16 [56%]; OR, 7.0; 95% CI, 1.2-40.8; P = .05 and 17/20 [85%] vs 7/16 [44%]; OR, 7.3; 95% CI, 1.5-35.2; P = .01, respectively). Partial or complete remission was documented in 11/31 (36%) cats and was associated with both short (OR, 3.3; 95% CI, 1.7-6.5; P < .001) and long-term survival (P = .003). Conclusion and Clinical Importance: Cats with PLN have a guarded prognosis, but achieving remission improves outcome. Cats presented with edema rather than azotemia are more likely to respond to treatment.


  • Open Access

    Evaluation of oxidative stress in dogs and cats with chronic kidney disease

    by Hilla Chen, Gilad Segev

    Background: Oxidative stress is a potential contributor to chronic kidney disease (CKD) progression but has not been evaluated in dogs and cats with CKD. Hypothesis: Oxidative stress is higher in animals with CKD compared with healthy controls and decreases with the advancing CKD stage. The aim of this study was to determine the presence and intensity of oxidative stress in dogs and cats at different CKD stages. Animals: Sixty dogs and 30 cats with naturally acquired CKD; 10 dogs and 14 cats, healthy controls. Methods: Analytical cross-sectional study. Oxidative stress was evaluated by measuring the urinary concentration of F2-isoprostane (uF2-IsoPs) normalized to urinary creatinine. Results: Urinary F2-isoprostanes normalized to urinary creatinine of healthy dogs and of dogs with CKD Stages 1 to 4 was 3.3 ng/mg, 4.7 ng/mg (range, 1.0-73.4), 2.4 ng/mg (range, 0.4-7.8), 0.52 ng/mg (range, 0.01-2.9), and 0.37 ng/mg (range, 0.01-0.6), respectively. Urinary F2-isoprostanes differed among CKD stages (P < .001), but not compared with controls. uF2-IsoPs of healthy cats and cats with CKD Stages 1 to 4 was 0.68 ng/mg (range, 0.2-1.4), 0.97 ng/mg (range, 0.4-1.8), 0.6 ng/mg (range, 0.002-2.0), 0.94 ng/mg (range, 0.3-2.3), and 0.2 ng/mg (range, 0.01-0.4). Urinary F2-isoprostanes differed among stages (P = .05) but not compared with healthy controls. Conclusion and Clinical Importance: Oxidative stress might be present in dogs and cats with CKD. Its magnitude declines as the disease progresses, therefore, it should be considered a potential therapeutic target mostly at the early stages of the disease.


  • Open Access

    Evaluation of the efficacy of a live Escherichia coli biotherapeutic product (asymptomatic bacteriuria E. coli 212)

    by Gilad Segev, Hilla Chen, Jonathan D. Dear, Beatriz Martínez López, Jully Pires, David J. Klumpp, Anthony J. Schaeffer, Jodi L. Westropp

    Background: Recurrent bacterial cystitis, often referred to as recurrent urinary tract infection (UTI), can be difficult to manage and alternative treatments are needed. Hypothesis/Objective: Intravesicular administration of asymptomatic bacteriuria (ASB) E. coli 212 will not be inferior to antimicrobial treatment for the management of recurrent UTI in dogs. Animals: Thirty-four dogs with >1 UTI in the 12 months before presentation. Methods: All dogs were deemed normal otherwise based on absence of abnormalities on physical examination, CBC, serum biochemical panel, and abdominal ultrasonography. Dogs were randomized to 1 of 2 treatment groups: Group 1 antimicrobials for 7 days or group 2 intravesicular administration of ASB E. coli 212. Owners were provided a voiding questionnaire regarding their dogs' clinical signs, which was completed daily for 14 days to assess clinical cure. Dogs were examined on days 7 and 14 to assess clinical cure, and urine specimens were submitted for urinalysis and bacterial culture. Results: Clinical cure rates for ASB E. coli 212–treated dogs were not inferior to 7 days of antimicrobial treatment with a 12% margin of difference to determine non-inferiority. No significant difference was found between the treatment groups on days 7 and 14 in the proportion of dogs achieving ≥50% or ≥75% reduction in their clinical score compared with baseline. Conclusions and Clinical Importance: These data suggest that intravesicular administration of ASB E. coli 212 is not inferior to antimicrobials for the treatment of recurrent UTI in dogs. This biotherapeutic agent could help alleviate the need for antimicrobials for some dogs with recurrent UTI, improving antimicrobial stewardship.

  • Open Access

    Short-term intra-individual variation of urinary biomarkers in dogs with stable chronic kidney disease

    by Hilla Chen, Lotem Maron, Gilad Segev

    Background: Active-ongoing kidney damage is present in animals with stable chronic kidney disease (CKD), as reflected by biomarkers in urine. Interpretation of serial messurements of biomarkers requires knowledge of its intra-individual variation. Aims: To evaluate the short-term intra-individual variation of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 (uNGAL, uKIM-1, respectively) in dogs with stable CKD, and to determine whether normalization to urinary creatinine (uCr) decreases variation. Animals: Twenty-five dogs with naturally-occurring stable CKD. Methods: Prospective, observational study. Dogs were diagnosed with CKD based on the International Renal Interest Society guidelines. Dogs were included only if the variation in serum creatinine concentration was 60% for uNGAL and uKIM-1, respectively, in serial measurements are higher than the normal expected variation and therefore might indicate need for further investigation for underlying causes of kidney damage.


  • Continuous renal replacement therapy is a safe and effective modality for the initial management of dogs with acute kidney injury

    by Hilla Chen, Sigal Klainbart, Efrat Kelmer, Gilad Segev

    OBJECTIVE: To describe the management of dogs with acute kidney injury (AKI) by continuous renal replacement therapy (CRRT), and to investigate the relationship between a prescribed CRRT dose, the hourly urea reduction ratio (URR), and the overall efficacy. ANIMALS: 45 client-owned dogs diagnosed with severe AKI, receiving 48 CRRT treatments at a veterinary teaching hospital. PROCEDURES: Retrospective study. Search of medical records of dogs with AKI managed by CRRT. RESULTS: Median serum urea and creatinine at CRRT initiation were 252 mg/dL [Inter quartile range (IQR), 148 mg/dL; range, 64 to 603 mg/dL] and 9.0 mg/dL (IQR, 7 mg/dL; range, 4.3 to 42.2 mg/dL), respectively. Median treatment duration was 21 hours (IQR, 8.8 hours; range, 3 to 32 hours). Systemic heparinization and regional citrate anticoagulation were used in 24 treatments each (50%). The prescribed median CRRT dose for the entire treatment was 1 mL/kg/min (IQR, 0.4 mL/kg/min; range, 0.3 to 2.5 mL/kg/min). The median hourly URR was 4% (IQR, 1%; range, 2% to 12%), overall URR was 76% (IQR, 30%; range, 11% to 92%) and median Kt/V was 2.34 (IQR, 1.9; range, 0.24 to 7.02). The CRRT dose was increased gradually from 0.9 mL/kg/min to 1.4 mL/kg/min (P < .001) and the hourly URR decreased from 6.5% to 5.5% (P = .05). The main complication was clotting of the extra-corporeal circuit, occurring in 6/48 treatments (13%). Twenty-four dogs (53%) survived to discharge. CLINICAL RELEVANCE: CRRT is safe when the prescription is based on the current veterinary guidelines for gradual urea reduction. Treatment efficacy can be maximized by gradually increasing the dose according to the actual URR.


  • Open Access

    Urinary interleukin‐6 is a potentially useful diagnostic and prognostic marker of acute kidney injury in dogs

    by Hilla Chen, Yochai Avital, Michal Mazaki‐Tovi, Itamar Aroch, Gilad Segev

    Background: Interleukin‐6 (IL6) is a pro‐inflammatory cytokine implicated in the pathophysiology of urinary tract diseases. The objective of this study was to evaluate the diagnostic and prognostic utilities of urinary IL6 (uIL6) in dogs with acute kidney injury (AKI) and other urinary tract diseases. Methods: Eighty client‐owned dogs were included and divided into four groups: AKI, chronic kidney disease (CKD), urinary tract infection and healthy controls. Urine samples were analysed for uIL6 and normalised to urinary creatinine (uIL6/uCr). Results: Dogs in the AKI group had higher uIL6/uCr compared with the control and CKD groups ( p < 0.001 and 0.012, respectively). Receiver operator characteristic (ROC) curve analysis of uIL6/uCr as a diagnostic marker for AKI had an area under the curve (AUC) of 0.91 (95% confidence interval [CI], 0.81–1.0) with 82% sensitivity and 90% specificity (cutoff point 4.5 pg/mg) when including the AKI and control groups. ROC analysis including AKI compared with all other groups had an AUC of 0.77 (95% CI, 0.67–0.87) for the diagnosis of AKI with sensitivity and specificity of 71% and 78%, respectively (cutoff point 10.4 pg/mg). The 30‐day mortality of the AKI group was 34%, and there was no difference in uIL6/uCr between survivors and non‐survivors of AKI. Conclusions: uIL6/uCr is a potentially sensitive and specific diagnostic marker for AKI in dogs.


  • Open Access

    Long-term outcome of dogs recovering from acute kidney injury: 132 cases

    by Mali Bar-Nathan, Hilla Chen, Dar Rimer, Gilad Segev

    Background: Information regarding long-term outcome of dogs recovering from acute kidney injury (AKI) is limited. Objectives: Determine the long-term outcome of dogs recovering from AKI and identify predictors for serum creatinine concentration (sCr) normalization and long-term outcome. Animals: One hundred thirty-two dogs with AKI that survived ≥30 days postdischarge. Methods: Retrospective study. Search of medical records of dogs diagnosed with AKI that survived to discharge. Follow-up data were retrieved from medical records and by telephone interviews with the owners or primary care veterinarians or both. Results: Estimated median survival time (MST) was 1322 days (95% confidence interval [CI], 1147-1626), and 76% of the dogs were alive at last contact. Normalization of sCr was documented in 55% of the dogs at discharge and in additional 20% during the follow-up period. The proportion of dogs with sCr normalization decreased with increase in AKI grade (P = .02). Long-term survival was not associated with sCr normalization (P = .63). Etiology was associated with the long-term outcome (P = .004). Conclusion and Clinical Importance: Long-term survival of dogs with AKI is longer than previously described. Normalization of sCr in 99 dogs (75%) occurred, either at discharge or within the follow-up period. Normalization of sCr was not associated with long-term survival. Estimated MST of dogs with sCr normalization was not different compared with dogs that developed azotemic chronic kidney disease (CKD), presumably because of slow CKD progression rate. Etiology is an important factor determining sCr normalization and long-term survival, emphasizing the importance of the reversibility of renal injury rather than its severity.


  • Therapeutic plasma exchange for the management of a type III hypersensitivity reaction and suspected immune‐mediated vasculitis assumed to be caused by human albumin administration in a dog

    by Sigal Klainbart, Gilad Segev, Efrat Kelmer, Hilla Chen

    Objective: To describe the successful treatment of a life‐threatening type III hypersensitivity reaction suspected to have been related to human serum albumin (HSA) administration in a dog with therapeutic plasma exchange (TPE).Case summary: A 3‐year‐old neutered male mixed breed dog was suspected to have developed immune‐mediated vasculitis 2 weeks after the administration of HSA (740 mg/kg) for the management of hypoalbuminemia resulting from septic peritonitis. The dog was presented with fever, edema, hypoalbuminemia (26 g/L [2.6 g/dL]; reference interval, 30–44 g/L [3.0‐4.4 g/dL]), and coagulopathy. The dog was treated with fresh frozen plasma (FFP) and glucocorticoids but remained hypoalbuminemic (18 g/L [1.8 g/dL]) and developed acute kidney injury (AKI). Over 4 days, 3 TPE treatments were performed, with a total of 2.7 plasma volumes exchanged. Replacement fluids consisted of a combination of FFP, hydroxyethyl starch 6%, and 0.9% saline solution. Following TPE treatments, serum albumin concentration increased (from 18 g/L [1.8 g/dL] to 25 g/L [2.5 g/dL]), serum creatinine concentration decreased (from 340 μmol/L [3.9 mg/dL] to 87 μmol/L [0.98 mg/dL]), and clotting times normalized (activated partial thromboplastin time decreased from 33 seconds to 14.5 seconds). There was a gradual but consistent clinical improvement of the edema and overall demeanor of the dog. No significant adverse effects were noted during the TPE treatments, and the dog was discharged after 8 days of hospitalization. Following discharge, the dog had complete clinical resolution of edema and AKI.New/unique information: This is the first report describing successful use of TPE for the management of an immune‐mediated reaction (type III hypersensitivity) following HSA administration.


  • Top Cited Papers
    Open Access

    Acute kidney injury in dogs: Etiology, clinical and clinicopathologic findings, prognostic markers, and outcome

    by Dar Rimer, Hilla Chen, Mali Bar-Nathan, Gilad Segev

    Background Acute kidney injury (AKI) is a common, potentially fatal condition. Objectives To characterize the etiologies, clinical and clinicopathologic findings, hospitalization period, and outcome of dogs with AKI and to identify markers of negative prognosis. Animals Two hundred forty-nine client-own dogs diagnosed with AKI and hospitalized at a veterinary teaching hospital. Methods Retrospective study. Search of medical records for dogs with AKI. Results Common clinical signs included lethargy (225/249, 90%), anorexia (206/249, 83%), and vomiting (168/249, 68%). Etiologies included ischemic/inflammatory (144/249, 58%), infectious (19/249, 8%), nephrotoxicosis (14/249, 6%), or other (13/249, 5%). Hospital-acquired AKI was diagnosed in 9% (23/249) of the dogs. Median presentation and peak serum creatinine (sCr) concentrations were 4 mg/dL (range, 1.1-37.9) and 4.6 mg/dL (range, 1.1-43.1), respectively. Dogs were classified to AKI grades as follows: Grade I, 6 (2%), Grade II, 38 (15%), Grade III, 89 (36%), Grade IV, 77 (31%), and Grade V, 39 (16%). One hundred and sixty-four (66%) dogs survived. There was a positive association between death and AKI grade (P = .009). The case fatality rate was higher among dogs with anuria compared with dogs without anuria (50% vs 28%, respectively; odds ratio [95% confidence interval]: 2.5 [1.39-4.6]; P = .002). Forty-seven (18.8%) dogs underwent hemodialysis, of which 60% survived. Conclusion and Clinical Importance Two-thirds of dogs with AKI survived. Hospital-acquired AKI was common. The severity of AKI, as reflected by presence of anuria, AKI grade, and other body organs involvement, was associated with the outcome.